Taxus Cardium Pharmaceuticals Group Inc. is a holding company that manages and operates a portfolio of medical technology platforms that are equity-based and potential royalty-driven investments as follows: (1) Angionetics, currently a majority-owned business unit focused on the late-stage clinical development and commercialization of Generx®; (2) the Excellagen® technology platform, now under management by Activation Therapeutics; (3) LifeAgain, an advanced medical data analytics (ADAPT®) technology platform focused on developing new and innovative products for the life insurance and healthcare sectors; and (4) Healthy Brands Collective, a functional food and nutraceutical company which acquired Taxus Cardium’s To Go Brands® business.